GC
ARRY

GMT Capital’s Array Biopharma Inc ARRY Stock Holding History

GMT Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-503,132
Closed -$2.52M – 94
2013
Q4 		$2.52M Sell
503,132
-1,808,559
-78% -$9.85M 0.05% 69
2013
Q3 		$14.4M Hold
2,311,691
– – 0.33% 47
2013
Q2 		$10.5M Buy
+2,311,691
New +$12.4M 0.24% 57

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GMT Capital's ARRY Position: Q1 2014 in Review

GMT Capital sold out of Array Biopharma Inc (ARRY) in Q1 2014, closing a stake of 503,132 shares — an estimated $2.52M sold.

GMT Capital first reported a position in ARRY in Q2 2013 and held it in 3 quarters. The position peaked at $14.4M in Q3 2013. 122 funds tracked by Wall St. Rank hold ARRY as of Q1 2014.

  • GMT Capital reported no remaining Array Biopharma Inc position as of Q1 2014 after selling out during the quarter.
  • GMT Capital sold 503,132 Array Biopharma Inc shares in Q1 2014, an estimated $2.52M.
  • GMT Capital first reported a position in Array Biopharma Inc in Q2 2013 and held it in 3 quarters.
  • GMT Capital's Array Biopharma Inc position peaked at $14.4M in Q3 2013.
  • 122 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2014.

Based on GMT Capital's 13F filing for Q1 2014, filed 15 May 2014.